Thermo Fisher Scientific Expands Direct-to-Patient Trials Service Offerings
The comprehensive offering now includes Clinical Site-to-Patient, Pharmacy-to-Patient and Depot-to-Patient services to enable clinical trial medication delivery directly to patients' homes.
Thermo Fisher Scientific's expanded Direct-to-Patient services build on its global Clinical Site-to-Patient program that launched earlier this year. The program can support any trial phase and a range of trial variables including Interactive Response Technology (IRT) systems, blinded/unblinded and home nursing providers. Clinical Site-to-Patient services are available in 47 countries and have supported more than 1,500 shipments to patients worldwide to help treat more than 25 different indications.
"Decentralized clinical trials have been on the rise even before the COVID-19 pandemic due to the location of study centers and the amount of time required for study visits being barriers to patient enrollment and ongoing participation," said Chris Armstrong, president, clinical trials business, Thermo Fisher Scientific. "As patients increasingly reach out to clinical trials sponsors to request receiving medication at home, it's critical to have a solution that delivers patients' medications safely and on time, without compromising trial quality and speed."
To read the full release, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
